Gene: FGD5

152273
ZFYVE23
FYVE, RhoGEF and PH domain containing 5
protein-coding
3p25.1
Ensembl:ENSG00000154783 MIM:614788 Vega:OTTHUMG00000155556 UniprotKB:Q6ZNL6
NC_000003.12
SNP Mapped
2   ANCO-SNPs
ND|AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.226e-1 (AD)  4.056e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs1687320chr3:14853127 (GRCh38.p7)C>A / C>Gnicotine dependenceSNV(Single Nucleotide Variation)
rs13070730chr3:14831707 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MMRN20.849
FLT40.848
CARD100.834
ARHGEF150.826
PTPRB0.824
PODXL0.819
SVIL0.814
GIMAP80.81
SHE0.805
ETS10.8

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
C1orf53-0.323
RBM34-0.32
ASPDH-0.313
NKX2-8-0.296
NEU4-0.289
CLDND2-0.284
C17orf50-0.281
C19orf73-0.277
NDP-0.275
TH-0.266

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of FGD5 mRNA"23994337
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in increased expression of FGD5 mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
D000638AmiodaroneAmiodarone results in increased expression of FGD5 mRNA19774075
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in increased expression of FGD5 mRNA26377693
D019324beta-Naphthoflavonebeta-Naphthoflavone results in increased expression of FGD5 mRNA23994337
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased mutagenesis of FGD5 gene25435355
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of FGD5 mRNA27195522
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of FGD5 mRNA22228805
D004958Estradiol[Estradiol binds to ESR2 protein] which results in increased expression of FGD5 mRNA20404318
C006780bisphenol Abisphenol A results in decreased expression of FGD5 mRNA26063408
C006780bisphenol Abisphenol A affects the expression of FGD5 mRNA25181051
C018021cobaltous chloridecobaltous chloride results in decreased expression of FGD5 mRNA19320972
D003042CocaineCocaine results in increased expression of FGD5 mRNA17898221
D016572CyclosporineCyclosporine results in decreased expression of FGD5 mRNA27989131
C014347decitabinedecitabine affects the expression of FGD5 mRNA23300844
D002945CisplatinCisplatin affects the expression of FGD5 mRNA23300844
D004041Dietary FatsDietary Fats results in increased expression of FGD5 mRNA25016146
C118739entinostatentinostat results in increased expression of FGD5 mRNA26272509|2718838
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
D017313FenretinideFenretinide results in increased expression of FGD5 mRNA28973697
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of FGD5 mRNA"26251327
D009532NickelNickel results in decreased expression of FGD5 mRNA25583101
D009966OrphenadrineOrphenadrine affects the expression of FGD5 mRNA23665939
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of FGD5 mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
D010936Plant ExtractsPlant Extracts results in decreased expression of FGD5 mRNA23557933
D012999SomanSoman results in decreased expression of FGD5 mRNA19281266
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FGD5 mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of FGD5 mRNA23994337
C009495titanium dioxidetitanium dioxide results in increased expression of FGD5 mRNA23557971
D014050TolueneToluene results in increased expression of FGD5 mRNA22967744
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of FGD5 mRNA24935251|2627250
C057693troglitazonetroglitazone results in decreased expression of FGD5 mRNA28973697
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of FGD5 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of FGD5 mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in increased methylation of FGD5 gene29154799
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of FGD5 gene25560391
C025643vinclozolinvinclozolin affects the expression of FGD5 mRNA19015723
C029297vinylidene chloridevinylidene chloride results in decreased expression of FGD5 mRNA26682919

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005085guanyl-nucleotide exchange factor activity-ISS-  
GO:0005089Rho guanyl-nucleotide exchange factor activity-IEA-  
GO:0005515protein binding-IPI23455924  
GO:0031267small GTPase binding-ISS-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007010cytoskeleton organization-ISS-  
GO:0008360regulation of cell shape-ISS-  
GO:0030036actin cytoskeleton organization-ISS-  
GO:0035023regulation of Rho protein signal transduction-IEA-  
GO:0043087regulation of GTPase activity-ISS-  
GO:0046847filopodium assembly-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0001726ruffle-ISS-  
GO:0005737cytoplasm-ISS-  
GO:0005769early endosome-IEA-  
GO:0005783endoplasmic reticulum-IEA-  
GO:0005794Golgi apparatus-ISS-  
GO:0005856cytoskeleton-IEA-  
GO:0030027lamellipodium-ISS-  
GO:0032587ruffle membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal